In-person meeting
Eddy Lang (Task Force), Emily McDonald (Task Force), Melissa Brouwers (ERSC), Chantal Plante (PHAC), David Moher (ERSC), Laure Tessier (PHAC)
The Task Force held its hybrid meeting in Gatineau, Quebec. For those who could not be present, the meeting was also broadcasted via videoconference. Dr. Wilson and Dr. Grad opened the meeting and Task Force members approved the agenda. Dr. Wilson provided some brief guidelines on the proceedings of this meeting.
Roundtable introductions were done, and Dr. Wilson welcomed new staff of the Task Force.
The interim co-Chairs thanked everyone for their participation.
Dr. Abou-Setta presented an update on the methods manual and other ongoing items.
Ms. Barnhardt presented an update on the recent work of the Communications team and their ongoing initiatives specifically on Task Force member recruitment efforts.
Ms. Limburg and Ms. Chaikalis presented on the Topics, specifically seeking Task Force approval of sending various topics for confirmation. Ms. Limburg also provided information on the potential use of AMR as an outcome and the hold statement for the Obesity topic.
Mr. Traversy presented on the Evidence to Decision (EtD) framework and ensuing recommendations for other therapies for smoking cessation.
Ms. Pillay presented updates on the Cervical Cancer guideline, specifically the results for the benefits and harms for screening (KQ1, KQ3, & KQ4).
Ms. Limburg presented on the second part of the Topics, specifically presenting an update on topic prioritization and the Delphi process.
Dr. Maher presented an update on the Task Force evaluation that is currently in the process of being completed by PHAC.
The guideline Working Group Chairs provided brief updates for the following guidelines: Lung Cancer and Vitamin D/Calcium.
Ms. Beckett and Ms. Chandraraj provided updates on recent KT activities and initiatives. This update included information on recently published and upcoming guidelines, new and upcoming KT tools, dissemination activities, Task Force projects, Clinical Prevention Leaders (CPL) network and Task Force Public Advisors Network (TF-PAN).
The guideline Working Group Chairs provided brief updates for the following guidelines: Depression (adult and child/adolescent), Fragility Fractures, Diabetes type II, Falls, Hypertension, Hepatitis C, Opioids, PIP, and Prostate Cancer Screening.
Dr. Grad thanked everyone for attending. The October 2022 Task Force hybrid meeting was adjourned.